Opsona Therapeutics was a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.

[1][2][3] Based in Ireland, Opsona was a spin-out from Trinity College Dublin (TCD).

[4] Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.

[5] Opsona's research was primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity.

Opsona's main investors were international and life-science focused: